Michael Miller, MD, FACC, FAHA

Fewer U.S. adults aged 40 to 75 years are eligible for statin therapy for primary CVD prevention in the new PREVENT risk calculator compared with the older Pooled Cohort Equation, researchers reported.

The worlds of hypertension and CV medicine lost a giant with the passing of Elijah Saunders, MD, a longtime member of the Cardiology Today Editorial Board.

The field of preventive cardiology lost one of its great investigators, clinicians and mentors with the passing of Peter O. Kwiterovich Jr., MD, on Aug. 15. He died after a long battle with metastatic prostate cancer at age 74 years.

According to the National Cholesterol Education Program Adult Treatment Panel (NCEP ATP III), elevated triglycerides are a biomarker for increased risk of coronary heart disease (CHD). Elevations in serum triglycerides are associated with increased levels of atherogenic remnant lipoproteins. Because very low density lipoprotein (VLDL) cholesterol is the most available measure of atherogenic remnant lipoproteins, it can be combined with low density lipoprotein (LDL) to estimate the non-high density lipoprotein (non-HDL = total cholesterol-HDL, target for non-HDL <130 mg/dL) level thereby representing the concentrations of atherogenic lipoproteins more effectively than LDL alone.